Your session is about to expire
← Back to Search
Cannabinoid
Cannabidiol (CBD) for Radiculopathy
Phase 1 & 2
Waitlist Available
Led By Stephen Ross, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 post-initiation of treatment, week 2 post-initiation of treatment
Awards & highlights
Study Summary
This trial is designed to compare the effects of oral CBD to placebo in people with chronic spinal pain who are already taking opioids. It will last for two weeks, and safety and pain outcomes will be measured.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 post-initiation of treatment, week 2 post-initiation of treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 post-initiation of treatment, week 2 post-initiation of treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in CBD Plasma Levels
Change in Opioid Analgesic Plasma Levels
Secondary outcome measures
Pain
Change in Score on Pain Catastrophizing Scale (PCS)
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Cannabidiol (CBD)Active Control1 Intervention
Group II: Placebo (PCB)Placebo Group1 Intervention
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,370 Previous Clinical Trials
840,790 Total Patients Enrolled
1 Trials studying Radiculopathy
120 Patients Enrolled for Radiculopathy
National Institute on Drug Abuse (NIDA)NIH
2,472 Previous Clinical Trials
2,619,608 Total Patients Enrolled
Stephen Ross, MDPrincipal InvestigatorNYU Langone Health
5 Previous Clinical Trials
426 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The amount of pain medication you are taking will be measured using two references, one from the Centers for Medicaid and Medicare Services and another from the Centers for Disease Control and Prevention. This is to ensure safe and appropriate dosing of pain medication.
Research Study Groups:
This trial has the following groups:- Group 1: Cannabidiol (CBD)
- Group 2: Placebo (PCB)
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any open positions for this research project?
"From what is published on clinicaltrials.gov, it seems as if this trial is still looking for volunteers. The original posting was on February 3rd, 2022 with the most recent update occurring on August 25th, 2022."
Answered by AI
Could you please share any other notable studies that have used Cannabidiol (CBD)?
"83 studies are currently underway to investigate CBD's efficacy. 18 of those studies have reached Phase 3 clinical trials. The global spread of these 311 locations running CBD trials is led by Brazil, more specifically Ribeirao Preto in Sao Paulo."
Answered by AI
Share this study with friends
Copy Link
Messenger